73/100BABBVIE reports its Q4 FY2026 results on 3 February 2027. Analysts expect earnings per share of 3.89 USD and revenue of 18.33B USD.
In Q3 FY2026, reported on 30 October 2026, ABBVIE earned 3.82 USD a share against the 3.73 USD analysts expected (+2.4%), on revenue of 17.40B USD against 17.32B USD (+0.5%).
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth | Next-day move |
|---|---|---|---|---|---|---|---|---|---|---|
| Q2 FY2028 | 4.51 | — | — | — | 19.67B | — | — | — | — | |
| Q1 FY2028 | 4.04 | — | — | +17.68% | 18.58B | — | — | +12.55% | — | |
| Q1 FY2027 | 3.43 | — | — | +29.39% | 16.51B | — | — | +10.05% | — | |
| Q4 FY2026 | 3.89 | — | — | +43.54% | 18.33B | — | — | +10.29% | — | |
| Q3 FY2026 | 3.73 | 3.82 | +2.41% | +105.38% | 17.32B | 17.40B | +0.51% | +10.32% | -2.1% | |
| Q2 FY2026 | 3.61 | 3.65 | +1.11% | +22.90% | 16.80B | 16.99B | +1.11% | +10.16% | -2.4% | |
| Q1 FY2026 | 2.59 | 2.65 | +2.32% | +7.72% | 14.72B | 15.00B | +1.93% | +12.43% | +3.5% | |
| Q4 FY2025 | 2.65 | 2.71 | +2.26% | +25.46% | 16.41B | 16.62B | +1.25% | +10.04% | +0.8% | |
| Q3 FY2025 | 1.77 | 1.86 | +5.08% | -38.00% | 15.59B | 15.78B | +1.22% | +9.10% | -2.7% | |
| Q2 FY2025 | 2.88 | 2.97 | +3.13% | +12.08% | 15.03B | 15.42B | +2.62% | +6.65% | +3.4% | |
| Q1 FY2025 | 2.38 | 2.46 | +3.36% | +6.49% | 12.93B | 13.34B | +3.22% | +8.39% | +3.4% | |
| Q4 FY2024 | 2.98 | 2.16 | -27.52% | -22.58% | 14.83B | 15.10B | +1.82% | +5.60% | +3.4% | |
| Q3 FY2024 | 2.92 | 3.00 | +2.74% | +1.69% | 14.28B | 14.46B | +1.24% | +3.83% | +1.2% | |
| Q2 FY2024 | 2.57 | 2.65 | +3.11% | -8.93% | 14.02B | 14.46B | +3.14% | +4.31% | +1.6% | |
| Q1 FY2024 | 2.26 | 2.31 | +2.21% | -6.10% | 11.93B | 12.31B | +3.19% | +0.70% | +1.2% | |
| Q4 FY2023 | 2.76 | 2.79 | +1.09% | -22.50% | 12.98B | 14.30B | +10.20% | -5.42% | +1.5% | |
| Q3 FY2023 | 2.86 | 2.95 | +3.15% | -19.40% | 13.67B | 13.93B | +1.87% | -5.97% | +2.2% | |
| Q2 FY2023 | 2.79 | 2.91 | +4.30% | -13.65% | 13.52B | 13.87B | +2.58% | -4.92% | +1.3% | |
| Q1 FY2023 | 2.44 | 2.46 | +0.82% | -24.07% | 12.17B | 12.23B | +0.47% | -9.70% | +1.5% | |
| Q4 FY2022 | 3.54 | 3.60 | +1.69% | +8.76% | 15.33B | 15.12B | -1.37% | +1.58% | +2.3% | |
| Q3 FY2022 | 3.56 | 3.66 | +2.81% | +9.91% | 14.96B | 14.81B | -0.99% | +3.28% | -0.8% | |
| Q2 FY2022 | 3.31 | 3.37 | +1.81% | +8.36% | 14.66B | 14.58B | -0.56% | +4.47% | -2.3% | |
| Q1 FY2022 | 3.14 | 3.24 | +3.18% | +9.83% | 13.61B | 13.54B | -0.55% | +4.06% | +0.7% | |
| Q4 FY2021 | 3.29 | 3.31 | +0.61% | +13.36% | 14.95B | 14.89B | -0.44% | +7.42% | +1.5% | |
| Q3 FY2021 | 3.23 | 3.33 | +3.10% | +17.67% | 14.35B | 14.34B | -0.08% | +11.16% | +0.1% | |
| Q2 FY2021 | 3.11 | 3.11 | 0.00% | +32.91% | 13.96B | 13.96B | 0.00% | +33.90% | -0.7% | |
| Q1 FY2021 | 2.77 | 2.95 | +6.50% | +21.90% | 12.81B | 13.01B | +1.58% | +50.95% | +2.9% | |
| Q4 FY2020 | 2.85 | 2.92 | +2.46% | +32.13% | 13.73B | 13.86B | +0.96% | +59.21% | +1.5% | |
| Q3 FY2020 | 2.75 | 2.83 | +2.91% | +21.46% | 12.63B | 12.90B | +2.17% | +52.16% | +3.6% | |
| Q2 FY2020 | 2.24 | 2.34 | +4.46% | +3.54% | 9.76B | 10.43B | +6.85% | +26.29% | +1.1% | |
| Q1 FY2020 | 2.25 | 2.42 | +7.56% | +13.08% | 8.01B | 8.62B | +7.56% | +10.10% | -1.3% | |
| Q4 FY2019 | 2.19 | 2.21 | +0.91% | +16.32% | 8.63B | 8.70B | +0.91% | +4.80% | +2.8% | |
| Q3 FY2019 | 2.29 | 2.33 | +1.75% | +8.88% | 8.37B | 8.48B | +1.30% | +2.95% | +1.5% | |
| Q2 FY2019 | 2.21 | 2.26 | +2.26% | +13.00% | 8.07B | 8.26B | +2.26% | -0.28% | -0.8% | |
| Q1 FY2019 | 2.05 | 2.14 | +4.39% | +14.44% | 7.50B | 7.83B | +4.39% | -1.34% | +0.5% | |
| Q4 FY2018 | 1.92 | 1.90 | -1.04% | +28.38% | 8.48B | 8.31B | -2.06% | +7.31% | -4.3% | |
| Q3 FY2018 | 2.02 | 2.14 | +5.94% | +51.77% | 7.77B | 8.24B | +5.94% | +17.74% | +3.7% | |
| Q2 FY2018 | 1.98 | 2.00 | +1.01% | +40.85% | 8.15B | 8.28B | +1.52% | +19.21% | +1.0% | |
| Q1 FY2018 | 1.79 | 1.87 | +4.47% | +46.09% | 7.59B | 7.93B | +4.47% | +21.35% | +1.2% | |
| Q4 FY2017 | 1.44 | 1.48 | +2.78% | +23.33% | 7.53B | 7.74B | +2.78% | +13.88% | -0.7% | |
| Q3 FY2017 | 1.39 | 1.41 | +1.44% | +16.53% | 6.90B | 7.00B | +1.44% | +8.75% | -1.0% | |
| Q2 FY2017 | 1.40 | 1.42 | +1.43% | +12.70% | 6.85B | 6.94B | +1.43% | +7.63% | -0.7% | |
| Q1 FY2017 | 1.26 | 1.28 | +1.59% | +11.30% | 6.44B | 6.54B | +1.59% | +9.73% | -0.2% | |
| Q4 FY2016 | 1.20 | 1.20 | 0.00% | +6.19% | 6.80B | 6.80B | 0.00% | +6.19% | +0.7% | |
| Q3 FY2016 | 1.20 | 1.21 | +0.83% | +7.08% | 6.38B | 6.43B | +0.83% | +8.21% | -3.2% | |
| Q2 FY2016 | 1.20 | 1.26 | +5.00% | +16.67% | 6.14B | 6.45B | +5.00% | +17.84% | +1.1% | |
| Q1 FY2016 | 1.12 | 1.15 | +2.68% | +22.34% | 5.85B | 5.96B | +1.77% | +18.21% | -0.3% | |
| Q4 FY2015 | 1.12 | 1.13 | +0.89% | +26.97% | 6.34B | 6.40B | +0.89% | +17.39% | -0.9% | |
| Q3 FY2015 | 1.07 | 1.13 | +5.61% | +26.97% | 5.68B | 5.94B | +4.63% | +18.43% | +6.4% | |
| Q2 FY2015 | 1.06 | 1.08 | +1.89% | +31.71% | 5.37B | 5.48B | +1.89% | +11.14% | +1.9% | |
| Q1 FY2015 | 0.84 | 0.94 | +11.90% | +32.39% | 4.56B | 5.04B | +10.59% | +10.45% | +2.8% | |
| Q4 FY2014 | 0.85 | 0.89 | +4.71% | +8.54% | 5.27B | 5.45B | +3.49% | +6.67% | +0.6% | |
| Q3 FY2014 | 0.78 | 0.89 | +14.10% | +8.54% | 4.34B | 5.02B | +15.58% | +7.75% | -0.3% | |
| Q2 FY2014 | 0.76 | 0.82 | +7.89% | 0.00% | 4.57B | 4.93B | +7.89% | +4.99% | +1.1% | |
| Q1 FY2014 | 0.68 | 0.71 | +4.41% | +4.41% | 4.37B | 4.56B | +4.41% | +5.41% | +3.5% | |
| Q4 FY2013 | 0.82 | 0.82 | 0.00% | -18.00% | 5.11B | 5.11B | 0.00% | +13.38% | -3.8% | |
| Q3 FY2013 | 0.78 | 0.82 | +5.13% | — | 4.43B | 4.66B | +5.13% | — | +0.2% | |
| Q2 FY2013 | 0.79 | 0.82 | +3.80% | +5.13% | 4.52B | 4.69B | +3.80% | +4.43% | +0.6% | |
| Q1 FY2013 | 0.67 | 0.68 | +1.49% | — | 4.27B | 4.33B | +1.49% | — | -1.3% | |
| Q4 FY2012 | — | 0.96 | — | +30.97% | — | 5.21B | — | +7.03% | -0.9% | |
| Q4 FY2012 | 0.99 | 1.00 | +1.01% | +36.43% | — | 4.51B | — | -7.32% | -0.9% | |
| Q2 FY2012 | — | 0.78 | — | -20.00% | — | 4.49B | — | +5.11% | — | |
| Q4 FY2011 | — | 0.54 | — | +22.25% | — | 4.17B | — | +7.09% | — | |
| Q4 FY2011 | — | 0.73 | — | +64.72% | — | 4.86B | — | +24.82% | — | |
| Q3 FY2011 | — | 0.01 | — | — | — | 4.41B | — | — | — | |
| Q2 FY2011 | — | 0.98 | — | — | — | 4.27B | — | — | — | |
| Q4 FY2010 | — | 0.45 | — | — | — | 3.90B | — | — | — |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 18.00 | — | — | +10.36% | 79.40B | — | — | +7.78% |
| FY2027 | 16.31 | — | — | +16.76% | 73.67B | — | — | +8.87% |
| FY2026 | 13.97 | — | — | +39.70% | 67.67B | — | — | +10.64% |
| FY2025 | 9.94 | 10.00 | +0.61% | -1.19% | 60.97B | 61.16B | +0.32% | +8.57% |
| FY2024 | 10.08 | 10.12 | +0.37% | -8.91% | 56.04B | 56.33B | +0.52% | +3.71% |
| FY2023 | 11.13 | 11.11 | -0.19% | -19.90% | 54.05B | 54.32B | +0.50% | -6.44% |
| FY2022 | 13.76 | 13.87 | +0.77% | +9.21% | 58.27B | 58.05B | -0.37% | +3.30% |
The move is the shares' change on the trading day after the report: after a report after the close, the next day's close on the report day's; before the open, the report day's close on the day before's. Surprise is the reported figure against the analysts' average estimate.
From the last earnings call, the company's guidance and analysts' previews, and checked against the report when it comes.
The two immune-disease drugs are AbbVie's main growth engines and help offset falling Humira sales.
On average, analysts' EPS estimate was 4.7% off the result, either way, and their revenue estimate 2.6%, over the last 12 quarters.
See also:Forecast,EPS,Income statement
Source: Financial Modeling Prep
